SLDB

- Duchenne (SGT-003): SGT-003 has been generally well tolerated in the 53 participants dosed in the Phase 1/2 INSPIRE DUCHENNE clinical trial as of November 3, 2026 - - Solid has scheduled a Type C meeting with the FDA in late Q4 2026 to discuss the preliminary INSPIRE DUCHENNE SGT-003 data package and to seek guidance on a potential accelerated approval pathway for SGT-003 -…

- Obtaining Orphan designation from the European Commission reflects Solid’s commitment to the global development of SGT-212 for individuals living with Friedreich’s ataxia - - SGT-212 is a first-in-class dual route FA gene therapy designed to combine direct, MRI-guided delivery to the dentate nuclei with systemic delivery to reach cardiac and other systemic tissues - - Five…

Solid Biosciences has received orphan designation from the European Commission for its drug SGT-212, aimed at treating Friedreich’s ataxia. This designation supports the company’s global development efforts for the therapy.

CHARLESTOWN, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc.

UBS has started covering Solid Biosciences with a Buy rating and set a price target of $20. The analyst highlights the company’s potential in the biotech space.